Botulinum toxin type A therapy for hemifacial spasm

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 11, 2020, Pages

  Duarte, Gonçalo S ^a,b   Rodrigues, Filipe B ^a,b   Castelão, Mafalda ^a,b   Marques, Raquel E ^a,b   Ferreira, Joaquim ^a,b   Sampaio, Cristina ^c   Moore, Austen P ^d   Costa, João ^a,b  

^a UNIVERSITY OF LISBON   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES   (Portugal)

^c CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^d THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; MUSCLE RELAXANT AGENT;

CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL OUTCOME; CONSENSUS; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTRONIC HEALTH RECORD; FOLLOW UP; HEADACHE; HEMIFACIAL SPASM; HUMAN; INJECTION SITE PAIN; MALAISE; META ANALYSIS; MUSCLE WEAKNESS; PARALLEL DESIGN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SORE THROAT; SYSTEMATIC REVIEW;

BOTULINUM TOXINS, TYPE A; HEMIFACIAL SPASM; HUMANS; NEUROMUSCULAR AGENTS; PLACEBOS;

EID: 85096459626     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004899.pub3     Document Type: Review

References (86)

1. Colakoglu BD, Cakmur R, Uzunel F. Is It always necessary to apply botulinum toxin into the lower facial muscles in hemifacial spasm? A randomized, single-blind, cross-over trial. European Neurology 2011;65:286-90. x-wiley/crsRef/2913381
2. Jitpimolmard S, Tiamkao S, Laopaiboon. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: report of 175 cases. Journal of Neurology, Neurosurgery, and Psychiatry 1998;64(6):751-7. x-wiley/crsRef/2913383
3. Mezaki T, Kaji R, Kimura J, Ogawa N. Treatment of hemifacial spasm with type A botulinum toxin (AGN 191622): a dose finding study and the evaluation of clinical effect with electromyography. No To Shinkei – Brain and Nerve 1999;51:427-32. x-wiley/crsRef/2913385
4. Park YC, Lim JK, Lee DK, Doe Yi S. Botulinum A toxin treatment of hemifacial spasm and blepharospasm. Journal of Korean Medical Science 1993;8(5):334-40. x-wiley/crsRef/2913387
5. Price J, Farish S, Taylor H, O'Day J. Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. Ophthalmology 1997;104(5):865-8. x-wiley/crsRef/2913389
6. Sampaio C, Ferreira JJ, Simões F, Rosas MJ, Magalhães M, Martins R, et al. Dysbot: a single blind, randomized clinical trial to compare two different formulations of botulinum toxin type A. Movement Disorders 1995;10(3):387. x-wiley/crsRef/2913391
7. Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A – Dysport and Botox – assuming a ratio of 4:1. Movement Disorders 1997;12(6):1013-8. x-wiley/crsRef/2913392
8. Xiao L, Pan L, Li B, Zhou Y, Pan Y, Zhang X, et al. Botulinum toxin therapy of hemifacial spasm: bilateral injections can reduce facial asymmetry. Journal of Neurology 2018;265(9):2097-105. x-wiley/crsRef/14749200
9. Yoshimura DM, Aminoff MJ, Tami TA, Scott AB. Treatment of hemifacial spasm with botulinum toxin. Muscle & Nerve 1992;15:1045-9. x-wiley/crsRef/2913378
10. Yoshimura DM, Aminoff MJ, Tami TA. Botulinum toxin therapy for hemifacial spasm. Neurology 1990;40(Suppl 1):381(974S). x-wiley/crsRef/2913379
11. Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clinical and Experimental Ophthalmology 2013;42(3):254-61.
12. Abrams KR, Gillies CL, Lambert PC. Meta-analysis of heterogeneously reported trials assessing change from baseline. Statistics in Medicine 2005;24:3823-44.
13. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders 2013;28(7):863-73.
14. Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Medical Research Methodology 2002;2:3.
15. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin. Journal of Neuroscience 2008;28:3689–96.
16. Auger RG, Whisnant JP. Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984. Archives of Neurology 1990;47(11):1233-4.
17. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6.
18. Barker FG, Jannetta PJ, Bissonette DJ, Shields PT, Larkins MV, Jho HD. Microvascular decompression for hemifacial spasm. Journal of Neurosurgery 1995;82:201-10.
19. Batisti JP, Kleinfelder AD, Galli NB, Moro A, Munhoz RP, Teive HA. Treatment of hemifacial spasm with botulinum toxin type A: effective, long-lasting and well tolerated. Arquivos de Neuropsiquiatria 2017;75(2):87-91.
20. Bernardi B, Zimmerman RA, Savino PJ, Adler C. Magnetic resonance tomographic angiography in the investigation of hemifacial spasm. Neuroradiology 1993;35(8):606-11.
21. Boroff DA, Chen GS. On the question of permeability of the blood–brain barrier to botulinum toxin. International Archives of Allergy and Applied Immunology 1975;48:495–504.
22. Brożek JL, Guyatt GH, Schünemann HJ. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. Health and Quality of Life Outcomes 2006;4:69.
23. Cakmur R, Tataroglu C, Idiman F. Electrophysiologic observations on pathogenic mechanisms of hemifacial spasm: F-waves of the facial muscles and silent period evoked by transcranial magnetic stimulation. European Journal of Neurology 1999;6 Suppl:136.
24. Cardoso F, Jankovic J. Blepharospasm. In: Tsui J, Calne D, editors(s). Handbook of Dystonia. New York: Marcel Dekker, 1995:129-42.
25. Carpenter J, Kenward M. Multiple Imputation and its Application. 1st edition. John Wiley & Sons, Lda, 2013.
26. Carter JB, Patrinely JR, Jankovic J, McCrary JA, Boniuk M. Familial hemifacial spasm. Archives of Opthalmology 1990;108(2):249-50. [DOI: 10.1001/archopht.1990.01070040101040]
27. Castelão M, Marques RE, Duarte GS, Rodrigues FB, Ferreira J, Sampaio C, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Systematic Reviews 2017, Issue 12. Art. No: CD003633. [DOI: 10.1002/14651858.CD003633.pub3]
28. Cillino S, Raimondi G, Guépratte N, Damiani S, Cillino M, Di Pace F, et al. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes. Eye 2010;24(4):600-7.
29. Cohen J. Statistical Power Analysis in the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc., 1988.
30. Corbett MS, Higgins JP, Woolacott NF. Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. Research Synthesis Methods 2014;5(1):79-85. [DOI: 10.1002/jrsm.1090]
31. Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook.
32. Defazio G, Abbruzzese G, Girlanda P, Vacca L, Currà A, De Salvia R, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Archieves of Neurology 2002;59(3):418-20.
33. de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proceedings of the National Academy of Sciences of the United States of America 1999;96:3200–5.
34. Duarte GS, Castelão M, Rodrigues FB, Marques RE, Ferreira J, Sampaio C, et al. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No: CD004314. [DOI: 10.1002/14651858.CD004314.pub3]
35. Duarte GS, Rodrigues FB, Ferreira JJ, Costa J. Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo. Parkinsonism & Related Disorders 2018;56:16–9. [10.1016/j.parkreldis.2018.06.017]
36. Duchen LW. An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse. Journal of Neurological Sciences 1971;14:47-60.
37. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Oto-laryngologica 1993;113:400–4.
38. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 1992;45:769-73.
39. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics: Targets & Therapy 2010;4:325-32.
40. McMaster University (developed by Evidence Prime) GRADEpro GDT. Version assessed 3 January 2019. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.
41. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence – imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93.
42. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. San Diego, California: Academic Press, Inc, 1985.
43. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
44. Higgins JPT, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook.
45. Higgins JPT, Deeks JJ, Altman DG, editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook.
46. Higgins JPT, and Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook.
47. Holland RL, Brown MC. Nerve growth in botulinum toxin poisoned muscles. Neuroscience 1981;6:1167–79.
48. Hosoya T, Watanabe N, Yamaguchi K, Saito S, Nakai O. Three dimensional MRI of neurovascular compression in patients with hemifacial spasm. Neuroradiology 1995;37(5):350-2.
49. Jamjoon AB, Anderson RL, Jordan DR, Patrinely JR. Bilateral hemifacial spasm. Journal of Clinical Neuro-ophthalmology 1990;10:153-4.
50. Jankovic J. Botulinum toxin in clinical practice. Journal of Neurology, Neurosurgery, and Psychiatry 2004;75(7):951-7.
51. Jog M, Wein T, Bhogal M, Dhani S, Miller R, Ismail F, et al. Real world, long-term quality of life following therapeutic onabotulinumtoxinA treatment. Canadian Journal of Neurological Sciences [Journal Canadien des Sciences Neurologiques] 2016;43(5):687-96.
52. Jost WH, Kohl A. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. Journal of Neurology 2001;248(Suppl 1):I/21-4.
53. Juzans P, Comella J, Molgo J, Faille L, Angaut-Petit D. Nerve terminal sprouting in botulinum type A-treated mouse levator auris longus muscle. Neuromuscular Disorders: NMD 1996;6(3):177-85.
54. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6:e1000100. [DOI: 10.1371/journal.pmed.1000100]
55. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3]
56. Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance RN, Brookes ST, et al. Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs). Trials 2014;15:49.
57. Marques RE, Duarte GS, Rodrigues FB, Castelão M, Ferreira J, Sampaio C, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No: CD004315. [DOI: 10.1002/14651858.CD004315.pub3] [PMID: 27176573]
58. Matak I, Lacković Z. Botulinum toxin A, brain and pain. Progress in Neurobiology 2014;119-120:39–59.
59. Matak I, Lacković Z. Botulinum neurotoxin type A: actions beyond SNAP-25? Toxicology 2015;335:79-84.
60. Matsuura N, Kondo A. Trigeminal neuralgia and hemifacial spasm as false localizing signs in patients with a contralateral mass of the posterior cranial fossa. Journal of Neurosurgery 1996;84:1067-71.
61. Nagata S, Matsushima T, Fujii K, Masashi F, Kuromatsu C. Hemifacial spasm due to tumor, aneurysm, or arteriovenous malformation. Surgical Neurology 1992;38:204-9.
62. Nielsen VK. Pathophysiology of hemifacial spasm: II. Lateral spread of the supraorbital nerve reflex. Neurology 1984;34(4):427-31. [DOI: 10.1212/wnl.34.4.427]
63. Nielsen VK, Jannetta PJ. Pathophysiology of hemifacial spasm: III. Effects of facial nerve decompression. Neurology 1984;34(7):891-97. [DOI: 10.1212/wnl.34.7.891]
64. Palomar FJ, Mir P. Neurophysiological changes after intramuscular injection of botulinum toxin. Clinical Neurophysiology 2012;123(1):54–60. [DOI: 10.1016/j.clinph.2011.05.032]
65. Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 1999;354:259–68.
66. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006;295(6):676-80.
67. Rato ML, Duarte GS, Mestre T, de Carvalho M, Ferreira JJ. Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions. Lancet Neurology 2018;17(10):842. [DOI: 10.1016/S1474-4422(18)30310-7]
68. Rato ML, Duarte GS, Ferreira AN, Alves M, Mainoli B, Teodoro T, et al. Nocebo response in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism & Related Disorders 2019;65:13-9. [DOI: 10.1016/j.parkreldis.2019.04.015]
69. Nordic Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Centre, The Cochrane Collaboration, 2014.
70. Rodrigues FB, Duarte GS, Prescott D, Ferreira J, Costa J. Deep brain stimulation for dystonia. Cochrane Database of Systematic Reviews 2019, Issue 1. Art. No: CD012405. [DOI: 10.1002/14651858.CD012405.pub2]
71. Rosales RL, Arimura K, Takenaka S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle & Nerve 1996;19:488–96.
72. Rosales RL, Dressler D. On muscle spindles, dystonia and botulinum toxin. European Journal of Neurology 2010;17:71–80.
73. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Statistics in Medicine 1991;10:585–98.
74. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook.
75. Serrano-Duenas M. Hemifacial spasm, quality of life and depression. Revista de Neurologia 1999;29(12):1108-11.
76. Silva MA, Duarte GS, Camara R, Rodrigues FB, Fernandes RM, Abreu D, et al. Placebo and nocebo responses in restless legs syndrome: a systematic review and meta-analysis. Neurology 2017;88(23):2216-24. [DOI: 10.1212/WNL.0000000000004004]
77. Simpson LL. Identification of the major steps in botulinum toxin action. Annual Review of Pharmacology and Toxicology 2004;44:167-93.
78. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analysis - sometimes informative, usually misleading. BMJ 1999;318(7197):1548-51.
79. Sprik C, Wirtschafter JD. Hemifacial spasm due to intracranial tumor. An international survey of botulinum toxin investigators. Ophthalmology 1988;95:1042-5.
80. Stata. Version 15. College Station, TX, USA: StataCorp, 2017. Available from www.stata.com.
81. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. Journal of Clinical Epidemiology 2001;54(10):1046-55.
82. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38.
83. Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. Journal of Clinical and Aesthetic Dermatology 2014;7(2):31-9.
84. Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle & Nerve 1998;21:1740-7.
85. Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ. A systematic review identifies a lack of standardization in methods for handling missing variance data. Journal of Clinical Epidemiology 2006;59(4):342-53.
86. Duarte GS, Rodrigues FB, Castelão M, Esteves Marques RE, Ferreira J, Sampaio C, et al. Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No: CD004899. [DOI: 10.1002/14651858.CD004899.pub2]